<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33332190</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>02</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1527-7755</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>39</Volume>
            <Issue>7</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Mar</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</Title>
          <ISOAbbreviation>J Clin Oncol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial.</ArticleTitle>
        <Pagination>
          <StartPage>713</StartPage>
          <EndPage>722</EndPage>
          <MedlinePgn>713-722</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1200/JCO.20.01820</ELocationID>
        <Abstract>
          <AbstractText Label="PURPOSE">ADJUVANT-CTONG1104 (ClinicalTrials.gov identifier: NCT01405079), a randomized phase III trial, showed that adjuvant gefitinib treatment significantly improved disease-free survival (DFS) versus vinorelbine plus cisplatin (VP) in patients with epidermal growth factor receptor (<i>EGFR</i>) mutation-positive resected stage II-IIIA (N1-N2) non-small-cell lung cancer (NSCLC). Here, we report the final overall survival (OS) results.</AbstractText>
          <AbstractText Label="METHODS">From September 2011 to April 2014, 222 patients from 27 sites were randomly assigned 1:1 to adjuvant gefitinib (n = 111) or VP (n = 111). Patients with resected stage II-IIIA (N1-N2) NSCLC and <i>EGFR</i>-activating mutation were enrolled, receiving gefitinib for 24 months or VP every 3 weeks for four cycles. The primary end point was DFS (intention-to-treat [ITT] population). Secondary end points included OS, 3-, 5-year (y) DFS rates, and 5-year OS rate. Post hoc analysis was conducted for subsequent therapy data.</AbstractText>
          <AbstractText Label="RESULTS">Median follow-up was 80.0 months. Median OS (ITT) was 75.5 and 62.8 months with gefitinib and VP, respectively (hazard ratio [HR], 0.92; 95% CI, 0.62 to 1.36; <i>P</i> = .674); respective 5-year OS rates were 53.2% and 51.2% (<i>P</i> = .784). Subsequent therapy was administered upon progression in 68.4% and 73.6% of patients receiving gefitinib and VP, respectively. Subsequent targeted therapy contributed most to OS (HR, 0.23; 95% CI, 0.14 to 0.38) compared with no subsequent therapy. Updated 3y DFS rates were 39.6% and 32. 5% with gefitinib and VP (<i>P</i> = .316) and 5y DFS rates were 22. 6% and 23.2% (<i>P</i> = .928), respectively.</AbstractText>
          <AbstractText Label="CONCLUSION">Adjuvant therapy with gefitinib in patients with early-stage NSCLC and <i>EGFR</i> mutation demonstrated improved DFS over standard of care chemotherapy. Although this DFS advantage did not translate to a significant OS difference, OS with adjuvant gefitinib was one of the longest observed in this patient group compared with historic data.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhong</LastName>
            <ForeName>Wen-Zhao</ForeName>
            <Initials>WZ</Initials>
            <Identifier Source="ORCID">0000-0003-4302-9332</Identifier>
            <AffiliationInfo>
              <Affiliation>Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, and Guangdong Academy of Medical Sciences, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Qun</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Fudan University Affiliated Zhongshan Hospital, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mao</LastName>
            <ForeName>Wei-Min</ForeName>
            <Initials>WM</Initials>
            <AffiliationInfo>
              <Affiliation>Zhejiang Cancer Hospital, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Song-Tao</ForeName>
            <Initials>ST</Initials>
            <AffiliationInfo>
              <Affiliation>Fudan University Affiliated Zhongshan Hospital, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Lin</ForeName>
            <Initials>L</Initials>
            <Identifier Source="ORCID">0000-0001-7078-7767</Identifier>
            <AffiliationInfo>
              <Affiliation>Hunan Cancer Hospital, Changsha, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wei</LastName>
            <ForeName>Yu-Cheng</ForeName>
            <Initials>YC</Initials>
            <AffiliationInfo>
              <Affiliation>The Affiliated Hospital of Medical College Qingdao University, Qingdao, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Yong-Yu</ForeName>
            <Initials>YY</Initials>
            <AffiliationInfo>
              <Affiliation>Shenyang Chest Hospital, Shenyang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Chun</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Fujian Medical University Union Hospital, Fuzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cheng</LastName>
            <ForeName>Ying</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0001-9908-597X</Identifier>
            <AffiliationInfo>
              <Affiliation>Jilin Provincial Tumor Hospital, Changchun, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yin</LastName>
            <ForeName>Rong</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Jiangsu Cancer Hospital, Nanjing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Fan</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>The People's Hospital of Peking University, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ren</LastName>
            <ForeName>Sheng-Xiang</ForeName>
            <Initials>SX</Initials>
            <AffiliationInfo>
              <Affiliation>Shanghai Pulmonary Hospital, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Xiao-Fei</ForeName>
            <Initials>XF</Initials>
            <AffiliationInfo>
              <Affiliation>Tangdu Hospital, Xi'an, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Jian</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Peking University First Hospital, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Cheng</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Fujian Cancer Hospital, Fuzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Zhi-Dong</ForeName>
            <Initials>ZD</Initials>
            <AffiliationInfo>
              <Affiliation>Beijing Chest Hospital, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Shun</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>The First Hospital of China Medical University, Shenyang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Ke-Neng</ForeName>
            <Initials>KN</Initials>
            <AffiliationInfo>
              <Affiliation>Beijing Cancer Hospital, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Shi-Dong</ForeName>
            <Initials>SD</Initials>
            <AffiliationInfo>
              <Affiliation>Harbin Medical University Cancer Hospital, Harbin, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Lun-Xu</ForeName>
            <Initials>LX</Initials>
            <Identifier Source="ORCID">0000-0003-3964-5378</Identifier>
            <AffiliationInfo>
              <Affiliation>West China Hospital of Sichuan University, Chengdu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Ping</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Sichuan Cancer Hospital, Chengdu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Bu-Hai</ForeName>
            <Initials>BH</Initials>
            <AffiliationInfo>
              <Affiliation>The Northern Jiangsu People's Hospital, Yangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ma</LastName>
            <ForeName>Hai-Tao</ForeName>
            <Initials>HT</Initials>
            <AffiliationInfo>
              <Affiliation>The First Affiliated Hospital of Suzhou University, Suzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Jin-Ji</ForeName>
            <Initials>JJ</Initials>
            <Identifier Source="ORCID">0000-0002-8498-0119</Identifier>
            <AffiliationInfo>
              <Affiliation>Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, and Guangdong Academy of Medical Sciences, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yan</LastName>
            <ForeName>Hong-Hong</ForeName>
            <Initials>HH</Initials>
            <Identifier Source="ORCID">0000-0002-6228-2096</Identifier>
            <AffiliationInfo>
              <Affiliation>Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, and Guangdong Academy of Medical Sciences, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Xue-Ning</ForeName>
            <Initials>XN</Initials>
            <Identifier Source="ORCID">0000-0002-8346-2117</Identifier>
            <AffiliationInfo>
              <Affiliation>Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, and Guangdong Academy of Medical Sciences, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Si-Yang</ForeName>
            <Initials>SY</Initials>
            <AffiliationInfo>
              <Affiliation>Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, and Guangdong Academy of Medical Sciences, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Qing</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, and Guangdong Academy of Medical Sciences, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Yi-Long</ForeName>
            <Initials>YL</Initials>
            <Identifier Source="ORCID">0000-0002-3611-0258</Identifier>
            <AffiliationInfo>
              <Affiliation>Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, and Guangdong Academy of Medical Sciences, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>ClinicalTrials.gov</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>NCT01405079</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <PublicationTypeList>
          <PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType>
          <PublicationType UI="D003160">Comparative Study</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016448">Multicenter Study</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>17</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Clin Oncol</MedlineTA>
        <NlmUniqueID>8309333</NlmUniqueID>
        <ISSNLinking>0732-183X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="C512478">EGFR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="D066246">ErbB Receptors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>Q20Q21Q62J</RegistryNumber>
          <NameOfSubstance UI="D002945">Cisplatin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>Q6C979R91Y</RegistryNumber>
          <NameOfSubstance UI="D000077235">Vinorelbine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>S65743JHBS</RegistryNumber>
          <NameOfSubstance UI="D000077156">Gefitinib</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>J Clin Oncol. 2021 Mar 1;39(7):697-700</RefSource>
          <PMID Version="1">33417483</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017024" MajorTopicYN="N">Chemotherapy, Adjuvant</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002945" MajorTopicYN="N">Cisplatin</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D066246" MajorTopicYN="N">ErbB Receptors</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077156" MajorTopicYN="N">Gefitinib</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077235" MajorTopicYN="N">Vinorelbine</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>17</Day>
          <Hour>17</Hour>
          <Minute>15</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33332190</ArticleId>
        <ArticleId IdType="pmc">PMC8078324</ArticleId>
        <ArticleId IdType="doi">10.1200/JCO.20.01820</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Burdett S Pignon JP Tierney J, et al. : Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. Cochrane Database Syst Rev CD011430, 2015</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25730344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng H Li XJ Wang XJ, et al. : A meta-analysis of adjuvant EGFR-TKIs for patients with resected non-small cell lung cancer. Lung Cancer 137:7-13, 2019</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31520922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan Y Huang Q Gu C, et al. : Disease-free survival improved by use of adjuvant EGFR tyrosine kinase inhibitors in resectable non-small cell lung cancer: an updated meta-analysis. J Thorac Dis 9:5314-5321, 2017</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5757008</ArticleId>
            <ArticleId IdType="pubmed">29312741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pisters KM Evans WK Azzoli CG, et al. : Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline. J Clin Oncol 25:5506-5518, 2007</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17954710</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiu-Yi Zhi Jin-Ming Yu, and Yuan-Kai Shi. Chinese guidelines on the diagnosis and treatment of primary lung cancer (2015 version). Cancer 121:3165-3181, 2015. Cancer 122:162, 2016</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26747468</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eberhardt WE De Ruysscher D Weder W, et al. : 2nd ESMO Consensus Conference in Lung Cancer: Locally advanced stage III non-small-cell lung cancer. Ann Oncol 26:1573-1588, 2015</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25897013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ettinger DS Wood DE Aggarwal C, et al. : NCCN guidelines insights: Non-small cell lung cancer, version 1.2020. J Natl Compr Canc Netw 17:1464-1472, 2019</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31805526</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kris MG Gaspar LE Chaft JE, et al. : Adjuvant systemic therapy and adjuvant radiation therapy for stage I to IIIA completely resected non-small-cell lung cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update. J Clin Oncol 35:2960-2974, 2017</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28437162</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goldstraw P Chansky K Crowley J, et al. : The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 11:39-51, 2016</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26762738</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Colt HG Murgu SD Korst RJ, et al. : Follow-up and surveillance of the patient with lung cancer after curative-intent therapy: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143:e437S-e454S, 2013</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23649451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deng XF Jiang L Liu QX, et al. : Lymph node micrometastases are associated with disease recurrence and poor survival for early-stage non-small cell lung cancer patients: a meta-analysis. J Cardiothorac Surg 11:28, 2016</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4754980</ArticleId>
            <ArticleId IdType="pubmed">26883746</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mok TS Wu YL Thongprasert S, et al. : Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957, 2009</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19692680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhong WZ Wang Q Mao WM, et al. : Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): A randomised, open-label, phase 3 study. Lancet Oncol 19:139-148, 2018</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29174310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yue D Xu S Wang Q, et al. : Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): A randomised, open-label, phase 2 trial. Lancet Res Med 6:863-873, 2018</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30150014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pennell NA Neal JW Chaft JE, et al. : SELECT: A phase II trial of adjuvant erlotinib in patients with resected epidermal growth factor receptor-mutant non-small-cell lung cancer. J Clin Oncol 37:97-104, 2019</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6524649</ArticleId>
            <ArticleId IdType="pubmed">30444685</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31:103-115, 1975</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1100130</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gyawali B, Hey SP, Kesselheim AS: Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs. EClinicalMedicine 21:100332, 2020</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7201012</ArticleId>
            <ArticleId IdType="pubmed">32382717</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mauguen A Pignon JP Burdett S, et al. : Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: A re-analysis of meta-analyses of individual patients' data. Lancet Oncol 14:619-626, 2013</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3732017</ArticleId>
            <ArticleId IdType="pubmed">23680111</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oxnard GR Janjigian YY Arcila ME, et al. : Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib. Clin Cancer Res 17:6322-6328, 2011</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3186869</ArticleId>
            <ArticleId IdType="pubmed">21831955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou Q Song Y Zhang X, et al. : A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506). BMC Cancer 17:462, 2017</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5496179</ArticleId>
            <ArticleId IdType="pubmed">28673332</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kelly K Altorki NK Eberhardt WE, et al. : Adjuvant erlotinib versus placebo in patients with stage IB-IIIA non-small-cell lung cancer (RADIANT): A randomized, double-blind, phase III trial. J Clin Oncol 33:4007-4014, 2015</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26324372</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhong WZ Chen KN Chen C, et al. : Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non–small-cell lung cancer (EMERGING-CTONG 1103): A randomized phase II study. J Clin Oncol 37:2235-2245, 2019</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31194613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu YL Herbst RS Mann H, et al. : ADAURA: Phase III, double-blind, randomized study of osimertinib versus placebo in egfr mutation-positive early-stage NSCLC after complete surgical resection. Clin Lung Cancer 19:e533-e536, 2018</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29789220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu ST Xi J-J Zhong WZ, et al. : The unique spatial-temporal treatment failure patterns of adjuvant gefitinib therapy: A post hoc analysis of the ADJUVANT trial (CTONG 1104). J Thorac Oncol 14:503-512, 2019</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30521970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu YL Tsuboi M He J, et al. : Osimertinib in resected EGFR-mutated non–small-cell lung cancer. N Engl J Med 383:1711-1723, 2020</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32955177</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
